Transforming Translational Research at the University of Bristol (CiC 2016)

Lead Research Organisation: University of Bristol

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description Innovate UK Investment Accelerator (Massimo Antognozzi)
Amount £150,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2018 
End 07/2019
 
Description MRC Proximity to Discovery and Enterprise and Impact Development Fund (Jenny Bailey / Tristan Cogan)
Amount £35,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 08/2018
 
Description MRC Confidence in Concept collaboration with DST and Semefab 
Organisation Semefab (Scotland) Ltd
Country United Kingdom 
Sector Private 
PI Contribution Development of novel silicon diode dosimetry devices for radiotherapy verification
Collaborator Contribution Potential commercial partner
Impact • £32,500 in kind support provided by DST/Semefab • Considering licencing IP to IBA
Start Year 2017
 
Description MRC Confidence in Concept collaboration with Life Arc and Abzena (Richard Lee) 
Organisation Abzena plc
PI Contribution Selective Calcineurin Inhibition for the Treatment of Corticosteroid Resistant Diseases
Collaborator Contribution Abzena: discussions over scale up work LifeArc: supplied the resources, expertise and material to generate the CCR6 antibodies and provided access to their laboratories and generally assisted in the generation of the monoclonal antibody. They have 17 years' experience in therapeutic antibody development and dedicated laboratories for the generation of monoclonal therapeutic antibodies. They have a variety of robotic systems and assay systems to aid the development and engineering of antibodies and substantial protein chemistry and protein production facilities.
Impact • £78,559 in kind support from LifeArc • Awarded £58,000 grant from National Eye Research Centre • Project selected as Bristol's application to Jules Thorne Biomedical Award 2018 - no formal costs at outline but approx. £1M • £53,000 from Moorfields BRC for top up project • Abzena in line for scale up work
Start Year 2017
 
Description MRC Confidence in Concept collaboration with Life Arc and Abzena (Richard Lee) 
Organisation LifeArc
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Selective Calcineurin Inhibition for the Treatment of Corticosteroid Resistant Diseases
Collaborator Contribution Abzena: discussions over scale up work LifeArc: supplied the resources, expertise and material to generate the CCR6 antibodies and provided access to their laboratories and generally assisted in the generation of the monoclonal antibody. They have 17 years' experience in therapeutic antibody development and dedicated laboratories for the generation of monoclonal therapeutic antibodies. They have a variety of robotic systems and assay systems to aid the development and engineering of antibodies and substantial protein chemistry and protein production facilities.
Impact • £78,559 in kind support from LifeArc • Awarded £58,000 grant from National Eye Research Centre • Project selected as Bristol's application to Jules Thorne Biomedical Award 2018 - no formal costs at outline but approx. £1M • £53,000 from Moorfields BRC for top up project • Abzena in line for scale up work
Start Year 2017
 
Title Development of novel clinical platelet function analyser 
Description Development of novel clinical platelet function analyser 
IP Reference P120007GB 
Protection Patent application published
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact • Innovate UK ICURe project to validate technology in the workplace complete • UK priority patent application filed #P120007GB • NIHR i4i outline application planned
 
Company Name Ceryx Medical 
Description Ceryx Medical is developing bioelectronics based on unique, patent protected, chip technology which is able to mimic nerve centres within the body called Central Pattern Generators (CPGs). These CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate and even walking. 
Year Established 2017 
Impact N/A
Website http://www.ceryxmedical.com/
 
Company Name VITAMICA LIMITED 
Description Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol. 
Year Established 2018 
Impact • Awarded £13,000 Longitude Discovery Prize • Awarded £150,000 from Innovate UK Investment Accelerator • Applied for Biomedical Catalyst, £195K - unsuccessful • Innovate UK ICURe project to validate technology in the workplace complete • UK priority patent application filed #P123064GB • Spin out company, Vitamica, created • £200,000 of early stage investment into company • Currently undergoing another investment round • MRC P2D funding for student projects £4k • EPSRC NPIF grant - 3 month placement in company
Website https://www.vitamica.co.uk/